Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AXL siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
AXL siRNA is a small interfering RNA (siRNA) designed to silence the expression of the AXL receptor tyrosine kinase. AXL is a member of the TAM (Tyro3, Axl, Mer) family of receptor tyrosine kinases and is frequently overexpressed in various cancers, where it promotes epithelial-to-mesenchymal transition (EMT), metastasis, and drug resistance. By binding to and promoting the degradation of AXL mRNA via the RNA-induced silencing complex (RISC), AXL siRNA reduces AXL protein levels, thereby inhibiting downstream signaling pathways such as AKT and MAPK. Research applications include the treatment of ovarian, uterine, lung, and colon cancers, as well as the management of liver fibrosis and keloids. Delivery often requires specialized platforms like nanoparticles (e.g., p5RHH) to ensure stability and cellular uptake in vivo.
- Other names
- AXL small interfering RNAanti-AXL siRNA
02
Targets
AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on AXL siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AXL siRNA.